Research programme: Duchenne muscular dystrophy therapeutics - RASRx

Drug Profile

Research programme: Duchenne muscular dystrophy therapeutics - RASRx

Alternative Names: MMX 1902; RASRx 1902

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RASRx
  • Class
  • Mechanism of Action Angiotensin modulators; Renin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 15 Jun 2017 MMX 1902 receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 15 Jun 2017 RASRx plans clinical trials for Duchenne muscular dystrophy
  • 01 Mar 2017 Preclinical trials in Duchenne muscular dystrophy in USA (PO) before March 2017 (CureDuchenne pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top